ReviewCancer immunology, immunotherapy : CII2014
Bioinformatics for cancer immunotherapy target discovery.
Review in Cancer immunology, immunotherapy : CII, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Investigating the role of peptides in effective therapies against cancer.Cancer cell international · 2022Review
- Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?Frontiers in pharmacology · 2022Article
- Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer.Journal of immunology research · 2022Article
- Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes.Immune network · 2021Article
- Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.Frontiers in immunology · 2021Article
- Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer.PloS one · 2020Article
- Identification of prognosis-related alternative splicing events in kidney renal clear cell carcinoma.Journal of cellular and molecular medicine · 2019Article
- Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data.Immunogenetics · 2019Article
- Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer.Oncotarget · 2019Article
- Bioinformatic identification of candidate biomarkers and related transcription factors in nasopharyngeal carcinoma.World journal of surgical oncology · 2019Article
- Current status and future directions of cancer immunotherapy.Journal of Cancer · 2018Review
- MuPeXI: prediction of neo-epitopes from tumor sequencing data.Cancer immunology, immunotherapy : CII · 2017Article
- TANTIGEN: a comprehensive database of tumor T cell antigens.Cancer immunology, immunotherapy : CII · 2017Article
- Peptide vaccines in cancer-old concept revisited.Current opinion in immunology · 2017Review
- Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.Diagnostic pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.